Impax Laboratories Inc. shares rose in the extended session Monday after the drug maker said the Food and Drug Administration approved its generic version of Sanofi SA’s Renvela. Impax shares advanced 5.7% to $21.50 after hours. The company said sales of the sevelamer carbonate, the generic name for Renvela, are reflected in its earnings outlook of 55 cents to 70 cents a share this year. Analysts surveyed by FactSet expect earnings of 70 cents a share.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News